Table 1.
Characteristics of the described population.
| Characteristics | |
|---|---|
| Number of patients (n) | 4148 |
| Age (years), median (range interquartile [IQR]) | 52 (47–55) |
| Male sex, n (%) Female sex, n (%) |
2846 (69%) 1302 (31%) |
| Weight, median [IQR] | 69 [58–78] |
| Height, median [IQR] | 170 [164–176] |
| Concomitant drugs, n (%) | 1572 (37.9%) |
| Proton-pump inhibitors, n (%) | 225 (5.4%) |
| Patients treated with nevirapine, n (%) | 165 (4%) |
| Patients treated with raltegravir, n (%) | 518 (12.5%) |
| Patients treated with darunavir, n (%) | 412 (9.9%) |
| Patients treated with ritonavir, n (%) | 936 (22.6%) |
| Patients treated with atazanavir, n (%) | 721 (17.4%) |
| Patients treated with etravirine, n (%) | 102 (2.5%) |
| Patients treated with abacavir, n (%) | 137 (3.3%) |
| Patients treated with tenofovir, n (%) | 1612 (38.9%) |
| Patients treated with emtricitabine, n (%) | 1547 (37.3%) |
| Patients treated with maraviroc, n (%) | 340 (8.2%) |
| Patients treated with lopinavir, n (%) | 191 (4.6%) |